Antibodies Panel


Phage Display and Recombinant Antibody Services

Recombinant antibodies, unlike the traditional hybridoma antibodies, its unique advantages in customization, high-throughput production and large-scale antibody production. Due to their low lot-to-lot variability and high specificity, recombinant antibodies are being touted as the future of antibodies in research. This means the diverse set applications utilizing antibodies such as immunodiagnostics and other biologics-based analytical research can benefit greatly from recombinant antibodies. iReal Biotechnology provides a flexible, one-stop solution for recombinant antibody development needs.

The phage display is also a technology for the generation of high quality candidates for human and veterinary therapeutic applications.

  • Immune library from immunized animals or donors
  • High throughput screening system
  • Recombinant antibody production (several formats available)
The Advantage of Recombinant Antibodies

Recombinant Antibody
High lot-to-lot consistency
Animal-free antibody production
Increased sensitivity and higher affinity
Improved tissue penetration
Ease of engineering, manufacture, scalability thus available in bulk
Conventional Antibody

Lower antibody yield

Highly training & experienced technician

What are Recombinant Antibodies?
What are the Various Types of Recombinant Antibody Fragments?

  • Fv, variable fragment
  • scFv, single chain Fv in which light and heavy chain fragments
  • (scFv)2, fragment that consists of two scFv molecules connected by a disulfide bond
  • dsFv, variable fragment stabilized by additional intramolecular disulfide bond
  • Fab- and (Fab)2, fragments
  • VH, heavy chain variable domain 
  • A Single domain antibody (sdAb) 

Rabbit Recombinant Monoclonal  Antibody Service

Rabbit Recombinant Monoclonal Antibody Workflow

Rabbit Recombinant Monoclonal Antibody Workflow

VHH recombinant  antibody

VHH antibody, also known as Camelid single domain antibody (sdAb), is the recombinant variable domain derived from camelid heavy-chain-only antibody.

The small size (15 kDa) and high stability of VHH antibody make it a promising tool for disease diagnosis and treatment. For example thanks to their small size (15 kDa), VHH can be transported more easily through certain physiological barriers. Additionally, VHH antibody expresses well in many host systems, making it cost-effective for large-scale manufacturing

VHH Antibody vs. Conventional Mab

•Small Size

•Superior Stability

•Low Immunogenicity

•High Affinity and Specificity

•Versatile Production

•Easy Conjugation

•Robustness in Bioengineering
VHH Antibody
12 - 15 kD
Approximately 150 kD

Required Antigen Amount
≦1.5 mg
≦5 mg

Camelid VHH library screening
Hybridoma technology

High stability to heat, pH and denaturing agents
Thermal instability

Lot-to-Lot Consistency
Very high

 Lead Time
8-24 weeks
16-24 weeks
Output / Product and QC
Time course
The target of interest
membrane protein, small molecule,
post-translation modifications, etc.

Therapeutic / Diagnosis Applications

Available material, specificity,
deadlines, etc.

1st stage
Antigen design& preparation
Protein Immunization
Produce 2mg protein for
SDS-PAGE, Purity, Yield
3-4 weeks
Peptide Immunization
Synthesis 5mg protein for
2nd stage
Animal immunization

Standard immunization service :
2 Rabbit Within 5 times immunization
1 Alpaca Within 5 times immunization

Rabbit : Dot titer Alpaca : ELISA titer
8-12 weeks
3rd stage
scFv/VHH library
& phage display

scFv/VHH Phage Library Generation:
Prediction of library size and positive percentage
PBMC/Lymphocyte Collection
RNA extraction
cDNA synthesis/preparation
Phage vector
Library construction
Colony counting and sequencing
3-4 weeks
4th stage
Bio-panning and screening

3-5 rounds of bio-panning
Clone isolation
Validation : ELISA、DNA sequencing
1. Specific 1-5 clone sequences
and DNA
2. VHH/scFv antibody 0.5 mL
without purification
3. Phage validation through
phage ELISA data
3-4 weeks
Phage binding assay on ELISA
Individual clone binding assay on ELISA
Sequence analysis
5th stage:
Antibody expression & purification

Expression and purification
Transformation into E.coli and
SDS-PAGE result
0.5 mg-1.0 mg/Ab
2-3 weeks
ELISA titration
Titration in duplicate at least
10 serial dilution results